Your browser doesn't support javascript.
loading
Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.
Schmutzler, Rita K; Schmitz-Luhn, Björn; Borisch, Bettina; Devilee, Peter; Eccles, Diana; Hall, Per; Balmaña, Judith; Boccia, Stefania; Dabrock, Peter; Emons, Günter; Gaissmaier, Wolfgang; Gronwald, Jacek; Houwaart, Stefanie; Huster, Stefan; Kast, Karin; Katalinic, Alexander; Linn, Sabine C; Moorthie, Sowmiya; Pharoah, Paul; Rhiem, Kerstin; Spranger, Tade; Stoppa-Lyonnet, Dominique; van Delden, Johannes Jozef Marten; van den Bulcke, Marc; Woopen, Christiane.
Afiliação
  • Schmutzler RK; Center Familial Breast and Ovarian Cancer and Center of Integrated Oncology (CIO), University Hospital Cologne, Cologne, Germany.
  • Schmitz-Luhn B; Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health (ceres), University of Cologne, and Research Unit Ethics, University Hospital of Cologne, Cologne, Germany.
  • Borisch B; Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Devilee P; Leids Universitair Medisch Zentrum, Universiteit Leiden, Leiden, The Netherlands.
  • Eccles D; Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Hall P; Karolinska Institutet, Stockholm, Sweden.
  • Balmaña J; Vall d'Hebron Instituto de Oncologia (VHIO), Barcelona, Spain.
  • Boccia S; Sezione di Igiene, Instituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Dabrock P; Department of Woman and Child Health and Public Health - Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Emons G; Friedrich-Alexander-Universität, Erlangen, Germany.
  • Gaissmaier W; Uniklinik Göttingen, Georg-August-Universität Göttingen, Göttingen, Germany.
  • Gronwald J; Max-Planck-Institut für Bildungsforschung, Universität Konstanz, Konstanz, Germany.
  • Houwaart S; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Huster S; BRCA-Netzwerk, Bonn, Germany.
  • Kast K; Lehrstuhl für Öffentliches Recht, Sozial- und Gesundheitsrecht und Rechtsphilosophie, Ruhr-Universität Bochum, Bochum, Germany.
  • Katalinic A; Center Familial Breast and Ovarian Cancer and Center of Integrated Oncology (CIO), University Hospital Cologne, Cologne, Germany.
  • Linn SC; Institut für Krebsepidemiologie, Universität Lübeck, Lübeck, Germany.
  • Moorthie S; Departments of Medical Oncology and Molecular Pathology - Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pharoah P; PHG Foundation, University of Cambridge, Cambridge, United Kingdom.
  • Rhiem K; Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Spranger T; Center Familial Breast and Ovarian Cancer and Center of Integrated Oncology (CIO), University Hospital Cologne, Cologne, Germany.
  • Stoppa-Lyonnet D; Center for Life Science & Law, Universität Bonn, Bonn, Germany.
  • van Delden JJM; Institut Curie, Paris, France.
  • van den Bulcke M; UM Utrecht - Julius Center for Health Sciences and Primary Care, Universiteit Utrecht, Utrecht, The Netherlands.
  • Woopen C; Belgium Cancer Center (BCC), Brussels, Belgium.
Breast Care (Basel) ; 17(2): 208-223, 2022 Apr.
Article em En | MEDLINE | ID: mdl-35702492
Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Breast Care (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Breast Care (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha